roger

(from Pubmed)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ui
ds=12865908&dopt=Abstract

Br J Cancer. 2003 Jul 21;89(2):239-42.

A novel biweekly pancreatic cancer treatment schedule with gemcitabine,
5-fluorouracil and folinic acid.

Oncology Section, Department of Human Pathology and Oncology, Siena
University School of Medicine, Viale Bracci 11, 53100 Siena, Italy.

Pancreatic adenocarcinoma is a common disease considered to be poorly
responsive to antiblastic treatment. Recent clinical and preclinical results
suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU)
and folinic acid (FA) offers a clinical benefit in patients with advanced
pancreas adenocarcinoma. The aim of this phase II clinical trial was to
evaluate the antitumour activity and toxicity of a novel biweekly schedule
of this combination in patients with pancreatic adenocarcinoma. A total of
42 patients received a 30 min infusion of FA (100 mg m(-2)) and 5-FU (400 mg
m(-2)) (FUFA) on days 1-3, and GEM 1000 mg m(-2) on day 1 every 15 days. We
observed 13 objective responses (two complete, 11 partial) and 23 stable
diseases. The median time to progression was 9.75 months (95% Confidence
Interval (CI), 6.88-12.62) and the median overall survival was 13.10 months
(95% CI 9.64-16.56). There were seven cases of each grade III gastroenteric
and haematological toxicity. The GEM plus FUFA combination appears to be
well tolerated and very active in patients with pancreatic carcinoma.

j

I don't see "significant" there, especially when one considers the following:
http://groups.google.com/groups?hl=en&lr=&ie=UTF-8&selm=KyW97.994%243x.3689%40news.bc.tac.net

J (uncross-posted)